Cited 17 times in
Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고형준 | - |
dc.contributor.author | 김규아 | - |
dc.contributor.author | 김성수 | - |
dc.contributor.author | 변석호 | - |
dc.contributor.author | 이성철 | - |
dc.contributor.author | 이승규 | - |
dc.contributor.author | 임형택 | - |
dc.date.accessioned | 2016-02-04T11:49:31Z | - |
dc.date.available | 2016-02-04T11:49:31Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0950-222X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/141287 | - |
dc.description.abstract | PURPOSE: To investigate factors associated with good response to intravitreal bevacizumab (IVB) in central serous chorioretinopathy (CSC) patients. METHODS: We retrospectively reviewed 42 eyes of CSC patients of symptom duration more than 3 months who received a single or multiple successive IVBs on an as-needed basis (0.05 ml, 1.25 mg). High responders (HRs) were defined as complete resolution of subretinal fluid (SRF) on spectral domain optical coherence tomography (SD-OCT). Moderate responders (MRs) were defined as SRF resolution of 50-99% of pretreatment volume and poor responders (PRs) as SRF resolution <50%. Clinical, SD-OCT, fluorescein, and indocyanine green angiography findings were analyzed to find factors associated with HR. Descriptive statistics for all demographic and clinical variables were calculated, and comparisons were made using Wilcoxon's matched-pairs signed-rank test, the Mann-Whitney U-test for means with continuous data, Pearson's χ(2) test, and Fisher's exact test for categorical data. RESULTS: The mean number of IVB was 1.9. At postoperative 1 month, there were 10 (24%) HRs, 18 (43%) MRs, and 14 (33%) PRs. At the last follow-up (the mean 8.6 months), there were 25 HRs (60%), 9 MRs (21%), and 8 PRs (19%). Thicker subfoveal choroid (P=0.036), smaller lesion diameter (P=0.019), and better baseline best-corrected visual acuity (P=0.002) predicted HRs at postoperative 1 month. HR at the last follow-up was associated with classic pattern fluorescein angiography finding. CONCLUSIONS: Suboptimal effects of IVB on persistent CSC suggest primary IVB on selective cases with better vision, smaller lesion, and thicker choroid at baseline. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 732~740,quiz 741 | - |
dc.relation.isPartOf | EYE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Angiogenesis Inhibitors/administration & dosage | - |
dc.subject.MESH | Angiogenesis Inhibitors/therapeutic use* | - |
dc.subject.MESH | Bevacizumab/administration & dosage | - |
dc.subject.MESH | Bevacizumab/therapeutic use* | - |
dc.subject.MESH | Central Serous Chorioretinopathy/diagnosis* | - |
dc.subject.MESH | Central Serous Chorioretinopathy/drug therapy* | - |
dc.subject.MESH | Central Serous Chorioretinopathy/physiopathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorescein Angiography | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intravitreal Injections | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Subretinal Fluid/drug effects | - |
dc.subject.MESH | Tomography, Optical Coherence | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/antagonists & inhibitors | - |
dc.subject.MESH | Visual Acuity/physiology | - |
dc.title | Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | G A Kim | - |
dc.contributor.googleauthor | T H Rim | - |
dc.contributor.googleauthor | S C Lee | - |
dc.contributor.googleauthor | S H Byeon | - |
dc.contributor.googleauthor | H J Koh | - |
dc.contributor.googleauthor | S S Kim | - |
dc.contributor.googleauthor | C S Lee | - |
dc.identifier.doi | 10.1038/eye.2015.58 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00571 | - |
dc.contributor.localId | A00152 | - |
dc.contributor.localId | A00326 | - |
dc.contributor.localId | A01849 | - |
dc.contributor.localId | A02873 | - |
dc.contributor.localId | A02913 | - |
dc.contributor.localId | A03419 | - |
dc.relation.journalcode | J00886 | - |
dc.identifier.eissn | 1476-5454 | - |
dc.identifier.pmid | 25952951 | - |
dc.identifier.url | http://www.nature.com/eye/journal/v29/n6/full/eye201558a.html | - |
dc.contributor.alternativeName | Koh, Hyoung Jun | - |
dc.contributor.alternativeName | Kim, Gyuah | - |
dc.contributor.alternativeName | Kim, Sung Soo | - |
dc.contributor.alternativeName | Byeon, Suk Ho | - |
dc.contributor.alternativeName | Lee, Sung Chul | - |
dc.contributor.alternativeName | Lee, Seung Kyu | - |
dc.contributor.alternativeName | Rim, Tyler H. T. | - |
dc.contributor.affiliatedAuthor | Kim, Sung Soo | - |
dc.contributor.affiliatedAuthor | Koh, Hyoung Jun | - |
dc.contributor.affiliatedAuthor | Kim, Gyuah | - |
dc.contributor.affiliatedAuthor | Byeon, Suk Ho | - |
dc.contributor.affiliatedAuthor | Lee, Sung Chul | - |
dc.contributor.affiliatedAuthor | Lee, Seung Kyu | - |
dc.contributor.affiliatedAuthor | Rim, Tyler Hyungtaek | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 29 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 732 | - |
dc.citation.endPage | 741 | - |
dc.identifier.bibliographicCitation | EYE, Vol.29(6) : 732-741, 2015 | - |
dc.identifier.rimsid | 31458 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.